These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38231269)

  • 41. Analyzing the co-localization of substantia nigra hyper-echogenicities and iron accumulation in Parkinson's disease: A multi-modal atlas study with transcranial ultrasound and MRI.
    Ahmadi SA; Bötzel K; Levin J; Maiostre J; Klein T; Wein W; Rozanski V; Dietrich O; Ertl-Wagner B; Navab N; Plate A
    Neuroimage Clin; 2020; 26():102185. PubMed ID: 32050136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MRI of Motor and Nonmotor Therapy-Induced Complications in Parkinson's Disease.
    Donzuso G; Agosta F; Canu E; Filippi M
    Mov Disord; 2020 May; 35(5):724-740. PubMed ID: 32181946
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of magnetic resonance imaging in the diagnosis of Parkinson's disease: a review.
    Al-Radaideh AM; Rababah EM
    Clin Imaging; 2016; 40(5):987-96. PubMed ID: 27288741
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biomarkers in Parkinson's disease: Advances and strategies.
    Delenclos M; Jones DR; McLean PJ; Uitti RJ
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(Suppl 1):S106-10. PubMed ID: 26439946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuroimaging and neurophysiological evaluation of severity of Parkinson's disease.
    Kuribara T; Enatsu R; Kitagawa M; Arihara M; Sasagawa A; Hirano T; Suzuki H; Yokoyama R; Mikami T; Mikuni N
    J Clin Neurosci; 2020 Apr; 74():135-140. PubMed ID: 32070672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of imaging genetics analysis to explain degree of depression in Parkinson's disease.
    Won JH; Kim M; Park BY; Youn J; Park H
    PLoS One; 2019; 14(2):e0211699. PubMed ID: 30742647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imaging behavioural complications of Parkinson's disease.
    Valli M; Mihaescu A; Strafella AP
    Brain Imaging Behav; 2019 Apr; 13(2):323-332. PubMed ID: 28856542
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease.
    Romero K; Conrado D; Burton J; Nicholas T; Sinha V; Macha S; Ahamadi M; Cedarbaum J; Seibyl J; Marek K; Basseches P; Hill D; Somer E; Gallagher J; Dexter DT; Roach A; Stephenson D; ;
    Clin Transl Sci; 2019 May; 12(3):240-246. PubMed ID: 30706986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Integrative analysis of blood metabolomics and PET brain neuroimaging data for Parkinson's disease.
    Glaab E; Trezzi JP; Greuel A; Jäger C; Hodak Z; Drzezga A; Timmermann L; Tittgemeyer M; Diederich NJ; Eggers C
    Neurobiol Dis; 2019 Apr; 124():555-562. PubMed ID: 30639291
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preface.
    Politis M
    Int Rev Neurobiol; 2018; 141():xv-xvi. PubMed ID: 30314609
    [No Abstract]   [Full Text] [Related]  

  • 51. MRI T
    Lee H; Baek SY; Kim EJ; Huh GY; Lee JH; Cho H
    Neuroimage; 2020 May; 211():116625. PubMed ID: 32058001
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
    Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
    Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brain Motor Network Changes in Parkinson's Disease: Evidence from Meta-Analytic Modeling.
    Herz DM; Meder D; Camilleri JA; Eickhoff SB; Siebner HR
    Mov Disord; 2021 May; 36(5):1180-1190. PubMed ID: 33427336
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identifying and distinguishing of essential tremor and Parkinson's disease with grouped stability analysis based on searchlight-based MVPA.
    Cheng F; Duan Y; Jiang H; Zeng Y; Chen X; Qin L; Zhao L; Yi F; Tang Y; Liu C
    Biomed Eng Online; 2022 Nov; 21(1):81. PubMed ID: 36443843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective.
    Thobois S; Prange S; Scheiber C; Broussolle E
    Parkinsonism Relat Disord; 2019 Feb; 59():93-100. PubMed ID: 30181086
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An individualized prediction of time to cognitive impairment in Parkinson's disease: A combined multi-predictor study.
    Tang C; Zhao X; Wu W; Zhong W; Wu X
    Neurosci Lett; 2021 Sep; 762():136149. PubMed ID: 34352339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biomarkers of Parkinson's disease: current status and future perspectives.
    Wang J; Hoekstra JG; Zuo C; Cook TJ; Zhang J
    Drug Discov Today; 2013 Feb; 18(3-4):155-62. PubMed ID: 22982303
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of a prognostic MRI biomarker in early de novo Parkinson's disease.
    Zeighami Y; Fereshtehnejad SM; Dadar M; Collins DL; Postuma RB; Dagher A
    Neuroimage Clin; 2019; 24():101986. PubMed ID: 31514113
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What is NODDI and what is its role in Parkinson's assessment?
    Kamagata K; Hatano T; Aoki S
    Expert Rev Neurother; 2016; 16(3):241-3. PubMed ID: 26777076
    [No Abstract]   [Full Text] [Related]  

  • 60. Imaging the Nonmotor Symptoms in Parkinson's Disease.
    Yousaf T; Wilson H; Politis M
    Int Rev Neurobiol; 2017; 133():179-257. PubMed ID: 28802921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.